The Innovative Medicines Initiative (IMI)
The EU-AIMS project is funded by the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the European Union and the pharmaceutical industry association EFPIA.
The European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA http://www.efpia.org/) share responsibility for the operation and the implementation of the Innovative Medicine Initiative (IMI www.imi.europa.eu ). The legal entity to do this is the, so-called, IMI Joint Undertaking (IMI-JU) with its Governing Board, its Scientific Committee and its Executive Director (and offices), the latter issuing the calls for research activities and signing the Grant Agreement with the coordinating institution.
IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients. Through its unique and innovative funding scheme, IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training.
Whereas academic participants and SMEs in an IMI project are funded by the 7th Research Framework Programme, the industrial partners - that have to be EFPIA members - contribute their own funds, matching the amount of public spending at at least a 100%.
For more information on this new funding mechanisms and the calls please consult the IMI Web Site: http://www.imi.europa.eu